INMED PHARMACEUTIC COM NPV (OTCMKTS:IMLFF) is a Canadian-based medical marijuana play that has been seeing increasing interest among OTC traders. The stock has been moving moderately lower of late in what may well be a bullish consolidation above its major moving averages following the stock’s explosive breakout in late September and early October.
The company has recently been beefing up its roster, with the latest addition being the appointment of Alexandra D.J. Mancini , M.Sc., as Senior Vice President, Clinical and Regulatory Affairs. She struck us as sufficiently impressive – with over 30 years of global biopharmaceutical R&D experience with a particular emphasis on clinical development and regulatory affairs, including an outstanding track record, having supported the advancement of products through the regulatory process in the United States, Canada and Europe – that we thought we might take a deeper look at the technical team she has to work with in R&D.
INMED PHARMACEUTIC COM NPV (OTCMKTS:IMLFF), as you may recall, is a pre-clinical stage biopharmaceutical company that engages in the research and development of novel and cannabinoid-based therapies in Canada.
The company’s products under pre-clinical development stage include INM-750 for the treatment of epidermolysis bullosa; and INM-085 for the treatment of glaucoma. It is also developing various drugs for diseases, such as ocular, pain and inflammation, dermatology, central nervous system, metabolic, and respiratory.
The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.
The InMed team is one of its most impressive assets.
Dr. Sazzad Hossain, Ph.D., M.Sc. plays the role of Chief Scientific Officer. Dr. Hossain has more than 20 years of academic and industrial experience in new drug discovery and natural health product development. He was Group Leader and Senior Scientist at Biotechnology Research Institute of National Research Council Canada, Government of Canada’s prime biotechnology research organization where he set up pharmacology laboratory to evaluate safety and efficacy of new drugs under development in the areas of cancer, cardiovascular and ocular diseases.
Prior to joining the National Research Council Canada, he was at Xenon Pharmaceuticals in Vancouver, B.C, where was Associate Director of Pharmacology and led pharmacology teams targeting pain, inflammation and cardiovascular diseases. Dr. Hossain received his PhD in Biology from Moscow State Academy of Veterinary Medicine & Biotechnology and received post-doctoral training in the Department of Nutritional Science and Department of Medical Genetics of University of British Columbia. He was associate professor of pharmacology at Federal University of Minas Gerais, Brazil between 1988 -1996.
He is the author of more than 40 peer-reviewed papers, primarily in the pharmacology, genetics and nutritional sciences.
In other words, the man is truly a prolific leader in the field.
Dr. Ado Muhammad, MD, DPM, MFPM is Chief Medical Officer, forming the backbone of the brain trust. He has extremely proven credentials as well.
For example, prior to joining the InMed team, Muhammad was Associate Medical Director at GW Pharmaceuticals, one of the global leaders in the development of cannabinoid-based prescription medicines, which suggests he knows “how to play winning ball” – always an important consideration. He was also a team member in core clinical research and was in key decision-making regarding R&D and product commercialization.
Dr. Paul Anderson, Ph.D., acts as the gem of the Scientific Advisory Board. Dr. Anderson is a synthetic organic chemist by training with more than 30 years of experience in pharmaceutical research and development.
Following postdoctoral studies in bioorganic chemistry at the University of Cambridge, Dr. Anderson began his career in the pharmaceutical industry at Merck Frosst Canada Inc. He subsequently joined Boehringer Ingelheim and in more than 20 years with the company, held positions of increasing responsibility in the research organization including more than 12 years as head of the Boehringer Ingelheim research centers in Canada and in the United States.
While in Canada, Dr. Anderson and his team introduced several anti-viral drugs into pre-clinical and clinical development, including the first HCV protease inhibitor to be tested in humans. As head of research for Boehringer Ingelheim in the United States, Dr. Anderson and his team carried out research on autoimmune and cardiovascular diseases, advancing several compounds into pre-clinical development. He received his Ph.D. in organic chemistry at the University of Alberta.
Mr. Anderson is also a Consultant for the National Institutes of Health (NIH) Blueprint Neurotherapeutics Network (BPN).
With likely major catalysts just ahead in the space, the stock is holding important levels and may be worth a fresh look given the quality of the team at the helm.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of journaltranscript.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:
The Next Big Thing In Biotech?https://journaltranscript.com
Get our top rated alerts on the biotech sector
A new field of medicine needs attentionhttps://journaltranscript.com
Here are the reasons to invest in CMXC
Traders Need To Know This Nowhttps://journaltranscript.com
WallStreet is loading up on this stock. Find out why